1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow EZN-2279: new trials by email Literature Review of EZN-2279 trials Research Report on EZN-2279
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EZN-2279 in Patients With ADA-SCID EZN-2279, Adagen - ADA-SCID, Adenosine Deaminase Deficiency | Phase 3 | Completed | Leadiant Biosciences, Inc. | 7 | 2014-01-24 | 2020-04-16 |
Severe Combined Immunodeficiency (1) · Severe combined immunodeficiency due to adenosine deaminase deficiency (1)
Leadiant Biosciences, Inc. (1)
United States (1)